Our research in scleroderma related diseases begin in 1989 with the recognition and description of the Eosinophilia Myalgia Syndrome and its relationship to epidemic Eosinophilic Fasciitis. 

West Michigan Rheumatology was one of the early investigational sites for the Scleroderma Clinical Trials Consortium beginning in 1994 with the landmark “High dose, Low dose d-Penicillamine Trial”.   

We have continued this thread of investigation by evaluating the validity of theRodnan Scleroderma Skin Score (a primary outcome in generalized scleroderma studies) and the Raynaud’s  Condition Score (the primary outcome for all raynauds clinical  trials).  We have conducted a number of investigations of potential treatments including “d-Penicillamine”,  “Relaxin” for generalized, diffuse scleroderma,  “dasatimib” for pulmonary fibrosis in diffuse scleroderma, andscleroderma treatment strategies.  In 2015 – 2017 we were the second largest center in Cytori STAR StudyThis evaluated the effectiveness of injection of autologously harvested fat stem cells into the fingers of patients with scleroderma related hand contractures.  In 2016-8 we participated in the FocuSSCed StudyThis evaluated subcutaneous Actemra, an FDA approved treatment for RA, in early diffuse scleroderma. 

We have also participated in the design and conduct of several studies of potential therapies for raynauds phenomenon:   “oral iloprost“Vascana”, and “PF-00489791”.    October 2019 we commence the AURORA Study which evaluates the effect of intravenous iloprost for symptomatic raynauds in scleroderma.